Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Next Previous
X
Search
Trial Profile

A First-in-Human Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATG 101 (Primary)
  • Indications Adenocarcinoma; B-cell lymphoma; Colon cancer; Liver metastases; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms PROBE
  • Sponsors Antengene Corporation

    • Most Recent Events

    • 22 Mar 2024 According to an Antengene Corporation, completion of Phase I dose escalation and proceed to dose expansion in H1 2025.
    • 20 Mar 2024 According to an AEON Biopharma media release, the trial is currently in the sixth dose escalation cohort and the drug is approaching its biologically active dose with good tolerability
    • 08 Feb 2024 Planned number of patients changed from 482 to 40.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top